Mitazalimab is under clinical development by Alligator Bioscience and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase I drugs for Kidney Cancer (Renal Cell Cancer) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mitazalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mitazalimab (ADC-1013) is under development for the treatment of advanced solid tumors like non-small cell lung cancer (NSCLC), metastatic pancreatic ductal adenocarcinoma, cutaneous melanoma, prostate cancer, renal cell cancer, bladder cancer and transitional cell carcinoma (urothelial cell carcinoma). The drug candidate is administered intra-tumorally and through intravenous infusion. It acts by targeting CD40. It is a monospecific, IgG1 antibody. ADC-1013 is developed by using ALLIGATOR-13, a fully human antibody library, and FIND (Fragment INduced Diversity), an in vitro based antibody optimization technology. It is based on IMCAN concept. The drug candidate is a new molecular entity (NME).
Alligator Bioscience overview
Alligator Bioscience is a pharmaceuticals and healthcare company. The company’s pipeline products include ATOR-1015, ATOR-1017 and ALG.APV-527. The ADC-1013, is a human, monospecific, agonistic, IgG1 antibody used for immunotherapy of cancer; ATOR-1015, is a bispecific immune activating antibody intended for tumor-directed immunotherapy. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB, and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.
For a complete picture of Mitazalimab’s drug-specific PTSR and LoA scores, buy the report here.